bearish
MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors
621 Views17 May 2019 15:58
MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- The Week That Was in North Asia 🇰🇷 🇯🇵: Nexon, Japan CVS/Drugstores, Nissan/Renault, KOSPI Rebal27 May 2019
- ECM Weekly (25 May 2019) - ESR Cayman, Hansoh Pharma, Tai Hing, China East Edu, Haitong UniTrust25 May 2019
- ECM Weekly (18 May 2019) - MabPharm, Frontage, Mulsanne, Xinyi Energy, Helenbergh18 May 2019
- MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors17 May 2019
- MabPharm (迈博医药) IPO: Thoughts on Valuation (Part 2)15 Apr 2019
- MabPharma (迈博医药) IPO: Assembled for a Trade?21 Feb 2019
x